Every patient’s journey to a Primary Periodic Paralysis (PPP) diagnosis is different. The established diagnostic protocol can help speed up the path to treatment.
The average time from onset of symptoms to correct diagnosis is 26 years.2*
As a healthcare provider, you’re in a unique position to help someone with PPP get a diagnosis and start treatment.
If you think you may have a patient with PPP, follow the below protocol. The sooner you can diagnose them, the sooner they can start to gain greater control over their symptoms.
*Based on a survey of 66 self-selected patients over the age of 40 years with a clinical diagnosis of Primary Periodic Paralysis who sought support via the Internet.
Because PPP is so rare, many patients have a challenging time receiving an accurate diagnosis.3
Diagnosing a patient with PPP can be a straightforward process by following the established protocol below.
In a sponsored roundtable discussion, expert clinicians in the field created a white paper that includes a detailed diagnostic algorithm for Primary Periodic Paralysis, which can help you identify PPP in patients and speed up their path to treatment.
Signs and symptoms (attacks) of PPP are often nonspecific and may have varying clinical presentations among patients.
In a study* of patients with hyperkalemic periodic paralysis surveyed about their disease:
*Based on a survey of 137 adults (>18 years of age) with a diagnosis of hyperkalemic PPP and a genetic diagnosis. Percentages are based on the total number of respondents who answered a given questions.
†Based on a survey of 66 self-selected patients over the age of 40 years with a clinical diagnosis of PPP who sought to support via the internet.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Concomitant Use of Aspirin or Other Salicylates
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.
The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.
Please see Full Prescribing Information.
Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.
By submitting this form, I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals® Terms of Use and Privacy Statement. I understand I can unsubscribe by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email, phone, etc) to Xeris CareConnection™ Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607.